ISAL 2017 | BiTES for the treatment of acute myeloid leukemia (AML) – results with AMG 330 in ex vivo study

Marion Subklewe

Marion Subklewe, MD of University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany provides an overview of her talk on CD33/CD3 bispecific antibody constructs for the treatment of acute myeloid leukemia (AML) held at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. Bispecific T-cell engagers (BiTES) have already entered the clinic in acute lymphoblastic leukemia (ALL) and Prof. Subklewe explains that they are working on a molecule targeting CD33 in AML. The agent called AMG 330 appears to be potent in lysing primary AML cells in their ex vivo culture system and they see the elimination of primary AML cells in approximately 80% of the cases. An international, first-in-human Phase I trial has been initiated and the first patients have been enrolled (NCT02520427).

Share this video